SCHEMBL29574318

SCHEMBL29574318

CCCNc1cc(Cl)nc2c1ncn2[C@H]1[C@@H]2OC(C)(C)O[C@@H]2[C@]2(C(=O)NC)C[C@H]12

nearest known ligand 0.53

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 17/20 0.53
▸ ADORA1 P30542 14/20 0.53
▸ HTR2B P41595 3/20 0.53
▸ SLC6A3 Q01959 2/20 0.53
▸ HRH2 P25021 1/20 0.52
▸ HTR5A P47898 1/20 0.52
▸ TMIGD3 P0DMS9 2/20 0.47
▸ ADRB3 P13945 1/20 0.47
▸ SLC6A2 P23975 1/20 0.47
▸ ADORA2A P29274 7/20 0.46
▸ HSP90B1 P14625 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26969055 0.94 HRH2 (0.49) ADORA3ADORA1HTR2BSLC6A3HRH2
SCHEMBL29573920 0.94 HRH2 (0.52) ADORA3ADORA1HTR2BSLC6A3HRH2
SCHEMBL29573437 0.91 HRH2 (0.51) ADORA3ADORA1HTR2BSLC6A3HRH2
SCHEMBL29574766 0.91 HRH2 (0.51) ADORA3ADORA1HTR2BSLC6A3HRH2
SCHEMBL29573475 0.89 HRH2 (0.49) ADORA3ADORA1HTR2BSLC6A3HRH2
SCHEMBL29573869 0.88 HRH2 (0.52) ADORA3ADORA1HTR2BSLC6A3HRH2
SCHEMBL29573861 0.88 HRH2 (0.53) ADORA3ADORA1HTR2BHRH2HTR5A
SCHEMBL29573817 0.86 HSP90B1 (0.52) ADORA3ADORA1HTR2BHRH2HTR5A
SCHEMBL29575011 0.84 ADORA3 (0.70) ADORA3ADORA1HTR2BSLC6A3TMIGD3
SCHEMBL26969054 0.84 ADORA3 (0.70) ADORA3ADORA1HTR2BSLC6A3TMIGD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4196219-A1 A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE Biointervene, Inc. (US) 2023-06-21 — — EP disclosed
WO-2022040241-A1 A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE BIOINTERVENE, INC. (US) 2022-02-24 — — WO disclosed
Send feedback